AbbVie Inc. (ABBV)
$
186.11
+0.49 (0.26%)
Key metrics
Financial statements
Free cash flow per share
8.7019
Market cap
328.7 Billion
Price to sales ratio
5.7306
Debt to equity
49.2176
Current ratio
0.7602
Income quality
3.8663
Average inventory
4.4 Billion
ROE
0.9559
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide, offering a diverse portfolio of therapies. The company reported a substantial revenue of $56,334,000,000.00 reflecting its strong market presence. Among its key offerings are HUMIRA, an injection therapy for autoimmune and intestinal Behçet's diseases, and SKYRIZI, which treats moderate to severe plaque psoriasis in adults. Additionally, RINVOQ serves as a JAK inhibitor for moderate to severe active rheumatoid arthritis, while IMBRUVICA and VENCLEXTA are utilized for chronic lymphocytic leukemia and small lymphocytic lymphoma treatment. MAVYRET targets chronic HCV genotype 1-6 infections, and the company also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency. Furthermore, Synthroid is used for hypothyroidism, while Linzess/Constella addresses irritable bowel syndrome with constipation. Lupron targets advanced prostate cancer and other conditions, and Botox therapeutic is part of their offerings. AbbVie continues its innovation with ORILISSA, a treatment for endometriosis pain, and Duopa and Duodopa, which help manage Parkinson's disease. The company’s ophthalmic products include Lumigan/Ganfort for elevated intraocular pressure and Restasis, which boosts tear production. The gross profit ratio is 0.70 reflecting the efficiency of the company's production and sales operations. The earnings per share (EPS) is reported at $2.40 indicating the company's profitability on a per-share basis. Moreover, the net total of other income and expenses is -$5,421,000,000.00 reflecting non-core financial activities, while the weighted average number of shares outstanding is 1,769,000,000.00 highlighting the company's shareholder base. In the financial market, the stock is reasonably priced at $185.62 appealing to a broad range of investors. AbbVie has a high average trading volume of 8,004,303.00 indicating strong liquidity, and boasts a large market capitalization of $328,744,704,000.00 establishing it as a dominant player. It is a key player in the Drug Manufacturers - General industry, contributing significantly to the overall market landscape, and belongs to the Healthcare sector, driving innovation and growth. This robust combination of research, product diversity, and solid financial metrics underpins AbbVie's position as a leader in the pharmaceutical market.
Is AbbVie Inc. (ABBV) a good investment?
Investing in AbbVie Inc. (ABBV) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
What is AbbVie Inc. (ABBV)'s stock forecast?
Analysts predict AbbVie Inc. stock to fluctuate between $158.83 (low) and $218.66 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is AbbVie Inc.'s market capitalization?
As of 2025-05-30, AbbVie Inc.'s market cap is $328,744,704,000, based on 1,766,400,000 outstanding shares.
How does AbbVie Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., AbbVie Inc. has a Lower Market-Cap, indicating a difference in performance.
Does AbbVie Inc. pay dividends?
AbbVie Inc. pays dividends. The current dividend yield is 3.61%, with a payout of $1.64 per share.
How can I buy AbbVie Inc. (ABBV) stock?
To buy AbbVie Inc. (ABBV) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABBV. Place an order (Market, Limit, etc.).
What is the best time to invest in AbbVie Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did AbbVie Inc. perform in the last earnings report?
Revenue: $56,334,000,000 | EPS: $2.40 | Growth: -12.09%.
Where can I find AbbVie Inc.'s investor relations reports?
Visit https://www.abbvie.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for AbbVie Inc.?
You can explore historical data from here
What is the all-time high and low for AbbVie Inc. stock?
All-time high: $218.66 (2025-03-10) | All-time low: $101.81 (2021-01-29).
What are the key trends affecting AbbVie Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
prnewswire.com
Chicago-based institutions aim to create greater awareness for cancer advocacy and to support non-profit cancer organizations NORTH CHICAGO, Ill. , May 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced a multi-year partnership with the Chicago Cubs to support people living with cancer through a campaign called "Striking Out Cancer" which starts today when the Chicago Cubs play the Cincinnati Reds.
prnewswire.com
NEW YORK , May 30, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
zacks.com
ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.
seekingalpha.com
Money market funds are booming with $7.2 trillion in assets, offering attractive short-term yields, but rising fees and competition could shake things up. I believe we're nearing a turning point: lower rates may push massive capital into dividend stocks, boosting prices and driving down future yields. In the second half of the article, I highlight three high-quality dividend stocks I believe could significantly benefit from this money market rotation trend.
prnewswire.com
NEW YORK , May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
seekingalpha.com
Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 2025 and the average growth rate at 4.75%. 22 Aristocrats appear both undervalued and offer a projected long-term annualized return of at least 10%, based on dividend yield theory and earnings growth.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=150335&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=150289&wire=1 or contact Joseph E. Levi, Esq.
fool.com
The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- it could easily flare up again.
See all news
